Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Indiana University Infectious Diseases Research CRS
mi
from
Indianapolis, IN
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Indiana University Infectious Diseases Research CRS
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Department of Internal Medicine, University of Iowa Hospitals & Clinics CRS
mi
from
Iowa City, IA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Department of Internal Medicine, University of Iowa Hospitals & Clinics CRS
mi
from
Iowa City, IA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Bluegrass Care Clinic/University of Kentucky Research Foundation CRS
mi
from
Lexington, KY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Bluegrass Care Clinic/University of Kentucky Research Foundation CRS
mi
from
Lexington, KY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
550 Clinic -University of Louisville CRS
mi
from
Louisville, KY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
550 Clinic -University of Louisville CRS
mi
from
Louisville, KY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Tulane - Louisiana Community AIDS Research Program (T-LaCARP) CRS
mi
from
New Orleans, LA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Tulane - Louisiana Community AIDS Research Program (T-LaCARP) CRS
mi
from
New Orleans, LA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University CRS
mi
from
Baltimore, MD
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University CRS
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital CRS (MGH CRS)
mi
from
Boston, MA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital CRS (MGH CRS)
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS
mi
from
Boston, MA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Boston Medical Center CRS
mi
from
Boston, MA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Boston Medical Center CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Baystate Infectious Diseases Clinical Research CRS
mi
from
Springfield, MA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Baystate Infectious Diseases Clinical Research CRS
mi
from
Springfield, MA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hosp. CRS
mi
from
Detroit, MI
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hosp. CRS
mi
from
Detroit, MI
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
St. John Newland Medical Associates CRS
mi
from
Southfield, MI
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
St. John Newland Medical Associates CRS
mi
from
Southfield, MI
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center CRS
mi
from
Jackson, MS
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center CRS
mi
from
Jackson, MS
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Specialty Care Center CRS
mi
from
Omaha, NE
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Specialty Care Center CRS
mi
from
Omaha, NE
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
New Jersey Medical School Clinical Research Center CRS
mi
from
Newark, NJ
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
New Jersey Medical School Clinical Research Center CRS
mi
from
Newark, NJ
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Downtown CRS
mi
from
New York, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Downtown CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Beth Israel CRS
mi
from
New York, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Beth Israel CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
VA New York Harbor Healthcare System (NYHHS), NY Campus CRS
mi
from
New York, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
VA New York Harbor Healthcare System (NYHHS), NY Campus CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Chelsea CRS
mi
from
New York, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Chelsea CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Mount Sinai St. Luke's Morningside CRS
mi
from
New York, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Mount Sinai St. Luke's Morningside CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Columbia P&S CRS
mi
from
New York, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Columbia P&S CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Uptown CRS
mi
from
New York, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Uptown CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Rochester Adult HIV Therapeutic Strategies Network CRS
mi
from
Rochester, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Rochester Adult HIV Therapeutic Strategies Network CRS
mi
from
Rochester, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Chapel Hill CRS
mi
from
Chapel Hill, NC
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Chapel Hill CRS
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Duke University Medical Center CRS
mi
from
Durham, NC
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Duke University Medical Center CRS
mi
from
Durham, NC
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Greensboro CRS
mi
from
Greensboro, NC
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Greensboro CRS
mi
from
Greensboro, NC
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Medical Center CRS
mi
from
Winston-Salem, NC
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Medical Center CRS
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Cincinnati Clinical Research Site
mi
from
Cincinnati, OH
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Cincinnati Clinical Research Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Case Clinical Research Site
mi
from
Cleveland, OH
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Case Clinical Research Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Ohio State University CRS
mi
from
Columbus, OH
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Ohio State University CRS
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Division of Infectious Diseases Clinical Research Center- Drexel University CRS
mi
from
Philadelphia, PA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Division of Infectious Diseases Clinical Research Center- Drexel University CRS
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Penn Therapeutics Crs
mi
from
Philadelphia, PA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Penn Therapeutics Crs
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh CRS
mi
from
Pittsburgh, PA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh CRS
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
The Miriam Hospital Clinical Research Site (TMH CRS) CRS
mi
from
Providence, RI
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
The Miriam Hospital Clinical Research Site (TMH CRS) CRS
mi
from
Providence, RI
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina: Division of Infectious Diseases CRS
mi
from
Charleston, SC
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina: Division of Infectious Diseases CRS
mi
from
Charleston, SC
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Therapeutics (VT) CRS
mi
from
Nashville, TN
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Therapeutics (VT) CRS
mi
from
Nashville, TN
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Trinity Health and Wellness Center CRS
mi
from
Dallas, TX
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Trinity Health and Wellness Center CRS
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Dallas VA Medical Center CRS
mi
from
Dallas, TX
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Dallas VA Medical Center CRS
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
UT Southwestern HIV/ID Clinical Trials Unit CRS
mi
from
Dallas, TX
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
UT Southwestern HIV/ID Clinical Trials Unit CRS
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Houston AIDS Research Team CRS
mi
from
Houston, TX
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Houston AIDS Research Team CRS
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Michael E. DeBakey VAMC REPRIEVE CRS
mi
from
Houston, TX
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Michael E. DeBakey VAMC REPRIEVE CRS
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University CRS
mi
from
Richmond, VA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University CRS
mi
from
Richmond, VA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Washington AIDS CRS
mi
from
Seattle, WA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Washington AIDS CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin, Inc. CRS
mi
from
Milwaukee, WI
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin, Inc. CRS
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Cooper Univ. Hosp. CRS
mi
from
Camden, NJ
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Cooper Univ. Hosp. CRS
mi
from
Camden, NJ
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Abbott Northwestern Hospital CRS
mi
from
Minneapolis, MN
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Abbott Northwestern Hospital CRS
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Oklahoma State University Center for Health Sciences CRS
mi
from
Tulsa, OK
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Oklahoma State University Center for Health Sciences CRS
mi
from
Tulsa, OK
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Mills Clinical Research CRS
mi
from
Los Angeles, CA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Mills Clinical Research CRS
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center CRS
mi
from
Boston, MA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Positive Health Clinic CRS
mi
from
Pittsburgh, PA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Positive Health Clinic CRS
mi
from
Pittsburgh, PA
Click here to add this to my saved trials